Publications by authors named "Liu-Ying Yan"
Article Synopsis
- The study aimed to compare the outcomes of radiation-induced hepatic toxicity (RIHT) in patients with hepatocellular carcinoma (HCC) receiving radiotherapy (RT) combined with anti-PD1 antibodies versus RT alone, and to identify factors predicting non-classic radiation-induced liver disease (ncRILD).
- Patients with unresectable HCC were retrospectively analyzed, with 30 receiving RT plus anti-PD1 and 66 receiving RT alone, using propensity score matching to ensure comparability.
- Results indicated similar RIHT rates between the two groups, with a higher frequency of elevated AST levels in the RT + PD1 group after matching; a nomogram was developed based on factors such as tumor number and patient age,
Article Synopsis
- The study focuses on non-classic radiation-induced liver disease (ncRILD) after intensity-modulated radiotherapy (IMRT) in patients with Child-Pugh grade B (CP-B) hepatocellular carcinoma (HCC).
- Among the 75 patients evaluated, 22.7% experienced ncRILD, with specific measurements of liver function and tumor characteristics noted.
- A nomogram was developed to predict the likelihood of ncRILD based on pre-treatment prothrombin time, number of tumors, and average liver dose during treatment, showing strong predictive accuracy.
Article Synopsis
- Intensity-modulated radiotherapy (IMRT) is a treatment option for patients with unresectable hepatocellular carcinoma (uHCC), and the study investigates how immune parameters can predict patient survival.
- * The research analyzed clinical data from 309 uHCC patients, finding that higher platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune inflammation (SII) after treatment correlated with poorer survival outcomes.
- * A prognostic nomogram was created from the findings, successfully predicting 3- and 5-year survival rates, with validation showing its effectiveness in a separate patient group.
Purpose: Stereotactic body radiotherapy (SBRT) may have significant immunomodulatory effects that enhance tumor response to immune checkpoint inhibitors. This phase 2 clinical trial was conducted to evaluate the safety and efficacy of combining palliative SBRT with camrelizumab (an anti-PD1 monoclonal antibody) in patients with unresectable hepatocellular carcinoma (uHCC).
Methods: Patients with uHCC, Child-Pugh A/B liver function, and at least one measurable lesion were enrolled between April 2020 and August 2022.